University of Houston Professor Haleh Ardebili (right) and Navid Khiabani, a graduate research assistant, are creating bendable batteries. Photo via UH.edu

A new breakthrough prototype out of the University of Houston was inspired by science fiction.

"As a big science fiction fan, I could envision a ‘science-fiction-esque future’ where our clothes are smart, interactive and powered,” according to a statement Haleh Ardebili, who last month published a paper on a new stretchable fabric-based lithium-ion battery in the Extreme Mechanics Letters.

“It seemed a natural next step to create and integrate stretchable batteries with stretchable devices and clothing," she said. "Imagine folding or bending or stretching your laptop or phone in your pocket. Or using interactive sensors embedded in our clothes that monitor our health.”

The battery uses conductive silver fabric as a platform and current collector, which stretches (or mechanically deforms) while allowing movement for electrons and ions. Traditional lithium batteries are quite rigid and use a liquid electrolyte, which are flammable and have potential risks of exploding.

The technology is only a prototype now, but Ardebili, who's the Bill D. Cook Professor of Mechanical Engineering at UH, and the paper's first author Bahar Moradi Ghadi, a former doctoral student, think the battery could have many applications, including in smart space suits, consumer electronics and implantable biosensors.

While it's just a prototype now, the technology has a lot of potential in the wearable tech space. Photo via UH.edu

The team's focus now is to ensure the battery is "as safe as possible" before it becomes available on the market.

“Commercial viability depends on many factors such as scaling up the manufacturability of the product, cost and other factors,” Ardebili said. “We are working toward those considerations and goals as we optimize and enhance our stretchable battery.”

Ardebili first conceptualized the product several years ago and has since earned several key wards and grants to support the design, including a five-year National Science Foundation CAREER Award in 2013, a New Investigator Award from the NASA Texas Space Center Grant Consortium in 2014 and an award from the US Army Research Lab in 2017.

A number of Houston-based organizations are working to create innovative batteries.

Earlier this summer, TexPower EV Technologies Inc. opened a 6,000-square-foot laboratory and three-ton-per-year pilot production line in Northwest Houston to help the University of Texas-born company to further commercialize its cobalt-free lithium-ion cathode, which can be used in electric vehicles.

Another Houston-based company Zeta Energy has also developed proprietary sulfur-based cathodes and lithium metal anodes that have shown to have higher capacity and density and better safety profiles than lithium sulfur batteries. The company landed a $4 million grant from the U.S. Department of Energy's ARPA-E Electric Vehicles for American Low-Carbon Living, or EVs4ALL, program, in January.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”